Mon Sep 23 23:18:00 UTC 2024: ## Rosen Law Firm Announces Lead Plaintiff Deadline in MacroGenics Class Action Lawsuit

**NEW YORK, Sept. 23, 2024** – The Rosen Law Firm, a leading investor rights law firm, is reminding investors who bought stock or sold puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, of the upcoming lead plaintiff deadline on September 24, 2024.

The lawsuit alleges that MacroGenics made false and misleading statements about the safety and efficacy of its drug vobramitamab duocarmazine (vobra duo) in a Phase 2 study for resistant prostate cancer, known as TAMARACK. The lawsuit claims these statements painted a misleading picture of the drug’s safety profile and the overall data from the study.

Investors who purchased stock or sold puts during the Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement.

Those interested in joining the class action can visit [https://rosenlegal.com/submit-form/?case_id=27488](https://rosenlegal.com/submit-form/?case_id=27488) or contact Phillip Kim, Esq. at 866-767-3653 or case@rosenlegal.com.

The Rosen Law Firm encourages investors to choose experienced counsel with a proven track record of success in class action litigation.

**About The Rosen Law Firm:**

The Rosen Law Firm is a global investor rights law firm specializing in securities class actions and shareholder derivative litigation. The firm has secured hundreds of millions of dollars for investors and has been consistently ranked among the top firms in the industry.

**Note:** No class has been certified yet. Individuals are not represented by counsel unless they retain one. They may choose their own counsel or remain an absent class member. Serving as lead plaintiff does not guarantee a share in any potential recovery.

Read More